Optical Coherence Tomography Predictors for a Favorable Vascular Response to Statin Therapy

J Am Heart Assoc. 2021 Jan 5;10(1):e018205. doi: 10.1161/JAHA.120.018205. Epub 2020 Dec 19.

Abstract

Background Specific plaque phenotypes that predict a favorable response to statin therapy have not been systematically studied. This study aimed to identify optical coherence tomography predictors for a favorable vascular response to statin therapy. Methods and Results Patients who had serial optical coherence tomography imaging at baseline and at 6 months were included. Thin-cap area (defined as an area with fibrous cap thickness <200 μm) was measured using a 3-dimensional computer-aided algorithm, and changes in the thin-cap area at 6 months were calculated. A favorable vascular response was defined as the highest tertile in the degree of reduction of the thin-cap area. Macrophage index was defined as the product of the average macrophage arc and length of the lesion with macrophage infiltration. Layered plaque was defined as a plaque with 1 or more layers of different optical density. In 84 patients, 140 nonculprit lipid plaques were identified. In multivariable analysis, baseline thin-cap area (odds ratio [OR] 1.442; 95% CI, 1.024-2.031, P=0.036), macrophage index (OR, 1.031; 95% CI, 1.002-1.061, P=0.036), and layered plaque (OR, 2.767; 95% CI, 1.024-7.479, P=0.045) were identified as the significant predictors for a favorable vascular response. Favorable vascular response was associated with a decrease in the macrophage index. Conclusions Three optical coherence tomography predictors for a favorable vascular response to statin therapy have been identified: large thin-cap area, high macrophage index, and layered plaque. Favorable vascular response to statin was correlated with signs of decreased inflammation. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01110538.

Keywords: layered plaque; macrophage; optical coherence tomography; statin; thin‐cap area.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Coronary Artery Disease* / diagnosis
  • Coronary Artery Disease* / drug therapy
  • Coronary Vessels* / diagnostic imaging
  • Coronary Vessels* / pathology
  • Correlation of Data
  • Female
  • Fibrosis / etiology
  • Fibrosis / pathology
  • Fibrosis / prevention & control
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Inflammation / pathology
  • Macrophages
  • Male
  • Middle Aged
  • Plaque, Atherosclerotic* / diagnostic imaging
  • Plaque, Atherosclerotic* / drug therapy
  • Plaque, Atherosclerotic* / pathology
  • Predictive Value of Tests
  • Tomography, Optical Coherence* / methods
  • Tomography, Optical Coherence* / statistics & numerical data
  • Treatment Outcome

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors

Associated data

  • ClinicalTrials.gov/NCT01110538